Resource Summary Report

Generated by dkNET on Aug 19, 2026

pBABEpuro-ERBB2

RRID:Addgene_40978
Type: Plasmid

Proper Citation

RRID:Addgene_40978

Plasmid Information

URL: http://www.addgene.org/40978

Proper Citation: RRID:Addgene_40978

Insert Name: ERBB2

Organism: Homo sapiens

Bacterial Resistance: Ampicillin

Defining Citation: PMID:22908275

Vector Backbone Description: Backbone Size:5200; Vector Backbone:pBABE-puro; Vector Types:Mammalian Expression, Retroviral; Bacterial Resistance:Ampicillin

Plasmid Name: pBABEpuro-ERBB2

Record Creation Time: 20220422T222212+0000

Record Last Update: 20260815T081440+0000

Ratings and Alerts

No rating or validation information has been found for pBABEpuro-ERBB2.

No alerts have been found for pBABEpuro-ERBB2.

Data and Source Information

Source: Addgene

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at dkNET .

Gagnon KA, et al. (2026) Oncogenic Alterations in PI3K Signaling Emulated Optogenetically Recapitulate Some Phenotypic Changes in Mammary Epithelia. ACS synthetic biology, 15(2), 561.

Dacheux MA, et al. (2025) BRAFV600E-Driven Lung Tumorigenesis Requires Ligand-Mediated Activation of ERBB Receptor Signaling. bioRxiv : the preprint server for biology.

Montero-Vergara J, et al. (2024) GRB2 is a BECN1 interacting protein that regulates autophagy. Cell death & disease, 15(1), 14.

Momeny M, et al. (2024) DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer. EMBO molecular medicine, 16(7), 1603.

Dennis M, et al. (2024) Her2 amplification, Rel-A, and Bach1 can influence APOBEC3A expression in breast cancer cells. PLoS genetics, 20(5), e1011293.

McKernan CM, et al. (2022) ABL kinases regulate translation in HER2+ cells through Y-box-binding protein 1 to facilitate colonization of the brain. Cell reports, 40(9), 111268.

Song X, et al. (2021) FGFR leads to sustained activation of STAT3 to mediate resistance to EGFR-TKIs treatment. Investigational new drugs, 39(5), 1201.

Reche-Perez FJ, et al. (2021) Single chain variable fragment fused to maltose binding protein: a modular nanocarrier platform for the targeted delivery of antitumorals. Biomaterials science, 9(5), 1728.

Akhand SS, et al. (2021) Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. NPJ breast cancer, 7(1), 5.

Koivu MKA, et al. (2021) Identification of Predictive ERBB Mutations by Leveraging Publicly Available Cell Line Databases. Molecular cancer therapeutics, 20(3), 564.

DiScala M, et al. (2020) Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. PloS one, 15(6), e0234146.

Kutys ML, et al. (2020) Uncovering mutation-specific morphogenic phenotypes and paracrine-mediated vessel dysfunction in a biomimetic vascularized mammary duct platform. Nature communications, 11(1), 3377.

Piasecka D, et al. (2020) Upregulation of HIF1-? via an NF-?B/COX2 pathway confers proliferative dominance of HER2-negative ductal carcinoma in situ cells in response to inflammatory stimuli. Neoplasia (New York, N.Y.), 22(11), 576.

Wang M, et al. (2019) A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Oncogene, 38(22), 4264.

Robichaux JP, et al. (2019) Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer

cell, 36(4), 444.

Ahn S, et al. (2019) Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. Cancer immunology research, 7(5), 773.

Takegawa N, et al. (2019) [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. International journal of cancer, 145(12), 3414.

Wang M, et al. (2019) Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Cell death discovery, 5, 153.

Shin DH, et al. (2018) Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Molecular cancer therapeutics, 17(9), 2024.

Kitowska K, et al. (2018) Progesterone impairs Herceptin effect on breast cancer cells. Oncology letters, 15(2), 1817.